See our science in action

GSK oncology is committed to the discovery and development of novel therapies, leveraging patient-driven science to improve outcomes for more patients

Belantamab mafodotin

Anti-BCMA ADC*

Belantamab mafodotin is an anti-BCMA ADC that consists of a mAb directed against BCMA joined to a microtubule-disrupting agent via a stable linker, currently being investigated in phase 1 and phase 2 clinical trials*[1,2]

GSK3359609

ICOS agonist mAb*



GSK3359609 is a humanized IgG4 ICOS agonist antibody that drives active cancer immunity through non-depleting T cell activation[3]

GSK3377794

NY-ESO-1 TCR T cell

GSK3377794 has an affinity-enhanced engineered T-cell receptor designed to target NY-ESO-1 and LAGE-1a antigens for the treatment of solid tumors and hematologic malignancies[4-6]

*In-license or other partnership with third party.

Immuno-Oncology

Transforming the way we approach cancer

The immune system plays an integral role in the fight against cancer, identifying and eliminating tumor cells through a process known as tumor immune surveillance[7]

Genetic Medicine

DNA damage and response to cancer

Inhibition of pathways that contribute to aberrant DNA repair in cancer cells is a promising area of research for increasing the effectiveness of current therapies and the discovery of novel treatment options[8,9]

ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; DNA, deoxyribonucleic acid; ICOS, inducible T-cell costimulator; IgG4, immunoglobulin G4; LAGE-1a, cancer testis antigen 2; mAb, monoclonal antibody NY-ESO-1, New York esophageal squamous cell carcinoma 1; TCR, T-cell receptor.

References:

See our science in action

GSK oncology is committed to the discovery and development of novel therapies, leveraging patient-driven science to improve outcomes for more patients

Belantamab mafodotin

Anti-BCMA ADC*

Belantamab mafodotin is an anti-BCMA ADC that consists of a mAb directed against BCMA joined to a microtubule-disrupting agent via a stable linker, currently being investigated in phase 1 and phase 2 clinical trials*[1,2]

GSK3359609

ICOS agonist mAb*



GSK3359609 is a humanized IgG4 ICOS agonist antibody that drives active cancer immunity through non-depleting T cell activation[3]

GSK3377794

NY-ESO-1 TCR T cell

GSK3377794 has an affinity-enhanced engineered T-cell receptor designed to target NY-ESO-1 and LAGE-1a antigens for the treatment of solid tumors and hematologic malignancies[4-6]

*In-license or other partnership with third party.

Immuno-Oncology

Transforming the way we approach cancer

The immune system plays an integral role in the fight against cancer, identifying and eliminating tumor cells through a process known as tumor immune surveillance[7]

Genetic Medicine

DNA damage and response to cancer

Inhibition of pathways that contribute to aberrant DNA repair in cancer cells is a promising area of research for increasing the effectiveness of current therapies and the discovery of novel treatment options[8,9]

ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; DNA, deoxyribonucleic acid; ICOS, inducible T-cell costimulator; IgG4, immunoglobulin G4; LAGE-1a, cancer testis antigen 2; mAb, monoclonal antibody NY-ESO-1, New York esophageal squamous cell carcinoma 1; TCR, T-cell receptor.

References:

1. Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy*. 2015;7(11):1187-1199.
2. Leung J, Suh W-K. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. *Immune Netw*. 2014;14(6):265-276.
3. McCormack E, Adams KJ, Hassan NJ, et al. Bi-specifi c TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. *Cancer Immunol Immunother*. 2013;62(4):773-785.
4. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1–specifi c TCR–engineered T cells mediate sustained antigen-specifi c antitumor effects in myeloma. *Nat Med*. 2015;21(8):914-921.
5. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J Clin Oncol*. 2011;29(7):917-924.
6. He Y, et al. Lymphocyte-activation gene-3, and important immune checkpoint in cancer. *Cancer Sci*. 2016;107:1193-1197.
7. Lord CJ, Ashworth A. The DNA damage response in cancer therapy. *Nature*. 2012;481(7381):287-294.
8. O'Connor MJ. Targeting the DNA damage response in cancer. *Mol Cell*. 2015;60(4):547-560.

SH020

GSK3359609
Inducible T-cell costimulator (ICOS) agonist IgG4 mAb

ICOS agonism without T cell depletion[1,2]



FPO

01:10/03:30

See scientific collaboration in action

GSK and Merck KGaA, Darmstadt, Germany, are working together to harness the potential of a novel, bifunctional immunotherapy with possible applications in multiple difficult-to-treat cancers

Bintrafusp alfa

Dual targeting of TGF-ß and PD-L1[1]



A bifunctional fusion protein composed of the extracellular domain of TGF-ßRII fused to a monoclonal antibody targeting PD-L1, aiming to function as a TGF-ß "trap"

Bintrafusp alfa is being developed in a strategic global alliance between GSK and Merck KGaA, Darmstadt, Germany.

Bintrafusp alfa (proposed INN for M7824) is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov. INN, international nonproprietary name; PD-L1, programmed cell death protein ligand 1; TGF-ß, transforming growth factor beta; TGF-ßRII, transforming growth factor beta receptor II.

References:

See scientific collaboration in action

GSK and Merck KGaA, Darmstadt, Germany, are working together to harness the potential of a novel, bifunctional immunotherapy with possible applications in multiple difficult-to-treat cancers

Bintrafusp alfa

Dual targeting of TGF-ß and PD-L1[1]



A bifunctional fusion protein composed of the extracellular domain of TGF-ßRII fused to a monoclonal antibody targeting PD-L1, aiming to function as a TGF-ß "trap"

Bintrafusp alfa is being developed in a strategic global alliance between GSK and Merck KGaA, Darmstadt, Germany.

Bintrafusp alfa (proposed INN for M7824) is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov. INN, international nonproprietary name; PD-L1, programmed cell death protein ligand 1; TGF-ß, transforming growth factor beta; TGF-ßRII, transforming growth factor beta receptor II.

References:

1. Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-ß. *Sci Transl Med.* 2018;10(424):eaan5488. doi:10.1126/scitranslmed.aan5488.


FPO
01:10/03:30

Alt. Version

See our science in action

GSK oncology is committed to the discovery and development of novel therapies, leveraging patient-driven science to improve outcomes for more patients

Belantamab mafodotin

Anti-BCMA ADC*

Belantamab mafodotin is an anti-BCMA ADC that consists of a mAb directed against BCMA joined to a microtubule-disrupting agent via a stable linker, currently being investigated in phase 1 and phase 2 clinical trials*[1,2]

GSK3359609

ICOS agonist mAb*



GSK3359609 is a humanized IgG4 ICOS agonist antibody that drives active cancer immunity through non-depleting T cell activation[3]

*In-license or other partnership with third party.

GSK3377794

NY-ESO-1 TCR T cell

GSK3377794 has an affinity-enhanced engineered T-cell receptor designed to target NY-ESO-1 and LAGE-1a antigens for the treatment of solid tumors and hematologic malignancies[4-6]

Immuno-Oncology

Transforming the way we approach cancer

The immune system plays an integral role in the fight against cancer, identifying and eliminating tumor cells through a process known as tumor immune surveillance[7]

Genetic Medicine

DNA damage and response to cancer

Inhibition of pathways that contribute to aberrant DNA repair in cancer cells is a promising area of research for increasing the effectiveness of current therapies and the discovery of novel treatment options[8,9]

ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; DNA, deoxyribonucleic acid; ICOS, inducible T-cell costimulator; IgG4, immunoglobulin G4; LAGE-1a, cancer testis antigen 2; mAb, monoclonal antibody NY-ESO-1, New York esophageal squamous cell carcinoma 1; TCR, T-cell receptor.

References:

See scientific collaboration in action

GSK and Merck KGaA, Darmstadt, Germany, are working together to harness the potential of a novel, bifunctional immunotherapy with possible applications in multiple difficult-to-treat cancers

Bintrafusp alfa

Dual targeting of TGF-ß and PD-L1[1]



A bifunctional fusion protein composed of the extracellular domain of TGF-ßRII fused to a monoclonal antibody targeting PD-L1, aiming to function as a TGF-ß “trap”

Bintrafusp alfa is being developed in a strategic global alliance between GSK and Merck KGaA, Darmstadt, Germany.

Bintrafusp alfa (proposed INN for M7824) is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov. INN, international nonproprietary name; PD-L1, programmed cell death protein ligand 1; TGF-ß, transforming growth factor beta; TGF-ßRII, transforming growth factor beta receptor II.

References: